GSK2200150A is a potent and selective inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) with an IC₅₀ of approximately 42 nM. It is primarily utilized in research settings to study necroptosis, inflammatory signaling, and related biological pathways implicated in diseases such as neurodegeneration, cancer, and inflammatory disorders. It is often employed in preclinical studies to investigate its potential as a therapeutic agent targeting RIPK1. Researchers use it to understand its mechanism of action, efficacy, and safety profile in cellular and animal models. Additionally, it serves as a valuable tool in drug discovery and development, helping to identify new treatment strategies. Its application is largely confined to laboratory experiments and is not approved for clinical use.